Kornimate/medical-research-clean huggingface dataset:
high altitude area- a risk factor for gastric perforation?

Conditions: Gastric Perforation

Summary: this is an original case series on soldiers evacuated from haa(high altitude area) over last one year(sept 2017- aug 2018) , of which 100% cases were found to have gastric antrum perforation. this is a deviation from the usual trend that is being noted in indian subcontinent where duodenal perforations are commonest.

introduction : this is an original case series on soldiers evacuated from haa(high altitude area) over last one year(sept 2017- aug 2018) , of which 100% cases were found to have gastric antrum perforation. this is a deviation from the usual trend that is being noted in indian subcontinent where duodenal perforations are commonest. discussion : high altitude associated dyspepsia is a common phenomenon and some studies done in high altitude population have recorded high incidence of antral gastritis and mucosal atrophy on histo-pathological evaluation. this is also supported by high incidence of h.pylori infection. the presence of atrophic gastric mucosa associated with antral gastritis, when exposed to hypobaric hypoxemic conditions faced by soldiers posted to heights above 15000ft , may leads to increased intra-luminal pressure and ischemia which probably predisposes individuals for gastric antrum perforations. conclusion : this is a relatively untouched topic as we have not found studies on high altitude related gastric perforations and probably this is the first case series of its kind. the acknowledgement of this phenomenon may pave way for further studies for defining the role of high altitude in gastric perforations.

Eligibility criteria:
inclusion criteria: * individuals located in high altitude area (\>10,000ft). * presented as perforation peritonitis. * intra-operatively found to be perforated peptic ulcers. exclusion criteria: * not located in high altitude area. * intra-operatively perfoarations sites other then stomach and duodenum.

Keywords: high altitude gastric antrum perforation mucosal atrophy intra luminal pressure
high-strength glass-ionomer dental restorations

Conditions: Dental Caries

Summary: the purpose of this study is to extend our knowledge concerning the clinical performance of two dental filling materials in molars. the study will compare two high-strength glass-ionomer filling materials. the investigators hypothesize that after two years (1) the clinical performance of both filling materials shows a similar survival rate, (2) the chemfil rock fillings show similar or higher incidence of fracture than fuji ix gp fillings.

in this longitudinal prospective randomized control clinical trial, posterior restorations (class ii) will be placed and evaluated for their clinical performance. the study will compare two restorative systems currently on the market in usa: both high-strength glass-ionomer (gi) restorative materials. the study restorations will be monitored for a period of up to 2 years.

Eligibility criteria:
inclusion criteria: * 7-16 year old * in need of one or two approximal fillings in molars exclusion criteria: * known allergies to calcium-aluminum-zinc-fluoro-phosphor-silicate glass or any other of glassionomer components

Keywords: dental caries proximal surfaces posterior teeth carious lesions tooth diseases dental restorations glass-ionomer
post tonsillectomy analgesia comparison after surgery site spray of local anesthesics

Conditions: Analgesia

Summary: check analgesia after tonsillectomy in adults

we hypothesize that a vaporization of local anesthetics in the tonsil lodge would reduce postoperative pain.

Eligibility criteria:
inclusion criteria: * tonsillectomy exclusion criteria: * gastric or duodenal ulcer * diabetes * kidney failure * chronic pain and fibromyalgia
lactoferrin infant feeding trial - lift_canada

Conditions: Preterm Infant; Very Low Birth Weight Infant; Morbidity;Newborn

Summary: this is a multicentre, phase iii, 2-arm, masked randomized controlled trial. the primary hypothesis is that oral bovine lactoferrin (blf), through its antimicrobial, antioxidant and anti-inflammatory properties, will reduce the rate of mortality or major morbidity in very low birth weight (vlbw) preterm infants.

almost 3,000 very low birth weight (vlbw), \<1500g preterm infants are born and treated in canada annually. about 1,200 either die or survive with severe brain or lung injury, retinopathy, late-onset sepsis or necrotizing enterocolitis (nec), each of which is associated with substantial risk of childhood disability. lactoferrin is an antimicrobial, antioxidant, anti-inflammatory iron-carrying, bifidogenic glycoprotein found in all vertebrates and in mammalian milk, leukocytes and exocrine secretions. however, most vlbw infants receive insufficient human lactoferrin (hlf) from human breast milk in the first months of life, resulting in suboptimal protection. because hlf is expensive, bovine lactoferrin (blf) has been considered as an alternate supplement to improve this suboptimal protection. lift is one of several ongoing trials using higher doses of bovine blf in the vlbw population (120-200 mg/kg/d). if lift confirms a 19% reduction in the relative risk of its primary outcome, blf will have a major impact, translating into thousands more intact survivors without major morbidity in australia, new zealand, canada, europe and worldwide each year. as \>90% of very preterm survivors at hospital discharge reach adulthood, this represents more than 19,000 life-years gained in canada alone each year, one of the largest gains in intact survival in any specialty since neonatal surfactant and antenatal steroids

Eligibility criteria:
an infant will be able to participate once a parent or guardian has provided a written informed consent and the infants must meet all of the following inclusion criteria: * \<1500 g at birth * 2-7 days old and not moribund * infant is considered to be stable by the clinical care team * has initiated feeds any infant meeting any of the following exclusion criteria will be excluded from participation in this study * severe congenital anomalies which are likely to cause death or known to contribute to an adverse neurodevelopmental outcome * major congenital gastrointestinal anomalies which will prevent an early approach to feeding * parents unable to provide informed consent
effect of tropicamide 0.5% vs tropicamide 1% on intraocular pressure of diabetic patients

Conditions: Type 2 Diabetes Mellitus; Type 1 Diabetes Mellitus

Summary: the aim of this study is to compare the effect of tropicamide 0.5% and tropicamide 1% on intraocular pressure and anterior chamber parameters in patients with diabetes mellitus.

patients with diabetes type 1 and type 2 older than 21 years of age, in the specialized clinic of kowsar hospital (semnan university of medical sciences) are examined. eligible individuals enter the study and are randomly assigned to group 1 or group 2. in each group, visual acuity measurement, slit lamp biomicroscopy and fundus examination are performed. intraocular pressure is measured with goldmann applanation tonometer. pupil size, refraction and keratometry are measured with two different autorefractokeratometers. keratometry, pupil size and other anterior chamber parameters are also evaluated by oculus pentacam imaging. then, the patients receive tropicamide 0.5% drops in group 1 and tropicamide 1% drops in group 2. 30 minutes later, all previous measurements are repeated. patients and the ophthalmologist and the data analyzer are unaware of the drug type.

Eligibility criteria:
inclusion criteria: * patients with diabetes mellitus type 1 and 2 exclusion criteria: * proliferative diabetic retinopathy * history of cataract surgery * severe nuclear and cortical cataract * glaucoma * intraocular pressure (iop) greater than 21 mmhg * familial history of glaucoma * narrow angle (van herick 1, 2) * cup to disc ratio greater than 0.5 * pregnancy * pterygium * corneal ectasia * history of keratorefractive surgery * corneal dystrophy * iris disorders * anisocoria * iris neovascularization * use of miotics or mydriatics
renal denervation with sterile irrigated deflectable ablation catheter used in renal artery in primary hypertension

Conditions: Primary Hypertension

Summary: the purpose of this study is to assess the safety and efficacy of renal denervation with sterile irrigated deflectable ablation catheter used in renal artery in primary hypertension in china.


Eligibility criteria:
inclusion criteria: * individual is ≥18 years and ≤65 years old. * primary hypertension. * screen criteria: individual who received a stable anti-hypertensive medication regimen including 2 or more anti-hypertensive medications of different classes prior to screening, and at the initial screening visit, he has an office systolic blood pressure(sbp)≥ 150mmhg, and ≤180mmhg, is entering the screening period after writing the informed consent. individual is receiving a 4week standard dose of amlodipine besylate (norvasc) and losartan potassium and hydrochlorothiazide tablets (hyzaar®), and has a sbp≥150mmhg and\<180mmhg at the second week after screening, and has an ambulatory 24-hour daytime average systolic blood pressure monitoring ≥140mmhg and \<170mmhg at the fourth week after screening. exclusion criteria: * secondary hypertension. * history of prior renal artery intervention including balloon angioplasty or stenting. * renal artery stenosis (≥50%) in either renal artery. * main renal arteries with \ 8mm in diameter. * main renal arteries with \<20mm in length. * estimated glomerular filtration rate (egfr) of \<40 ml/(min•1.73m2). * history of stroke or tia within 6 months prior to screening period. * history of acute coronary syndrome within 6 months prior to screening period. * structural heart disease without receiving effective treatment; coronary heart disease with β blockers; severe peripheral artery disease that affecting blood pressure measurement and other unqualified conditions evaluated by investigator. * heart failure (nyha classification ⅲ-ⅳ). * coagulation disorders associated with significant bleeding tendency, and history of other blood system diseases. * history of cancer. * type 1 diabetes mellitus; type 2 diabetes mellitus with target organ injuring. * acute or severe systemic inflammatory response syndrome. * any other serious medical condition unqualified to participate in this study evaluated by investigator.

Keywords: primary hypertension renal denervation
vascular function, fish protein hydrolysates and type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2

Summary: type 2 diabetes mellitus (t2dm) is a chronic metabolic disease of abnormal carbohydrate metabolism which is related with high morbidity and mortality rates caused by its complications. one of the major diabetes-related arterial phenotypes thought to be responsible for development of cardiovascular disease is endothelial dysfunction. nitric oxide (no) is a potent molecule derived of endothelium, which plays key role in control of vascular tone. in t2dm present endothelial dysfunction due to reduced no bioavailability. fish protein hydrolysates (fph) have been showed to present antioxidant peptides (and high value of ace inhibition activity. therefore, the present study aimed to examine whether single dose of fph ingestion would reversal macro- and microvascular endothelial dysfunction in t2dm.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus exclusion criteria: * history of symptomatic coronary artery disease; * stroke or other known atherosclerotic disease; * cancer; * hiv positive; * alcohol or drug abuse within the past 6 months previous the visit 1; * use any antioxidant supplementation

Keywords: vascular function type 2 diabetes mellitus fish protein hydrolysates
ureteroscopy combined with negative pressure sheath treatment of kidney stones

Conditions: Kidney Calculi

Summary: the removal rate, complication risk and operation time of ureteral soft scope combined with negative pressure suction sheath therapy for patients with high-load kidney stones (2-3cm) are still controversial. therefore, what is the safety and effectiveness of ureteral soft scope combined with negative pressure suction sheath treatment for patients with high-load kidney stones and stones combined with infection? this study will help to solve the problems of safety and effectiveness of ureteral soft scope combined with negative pressure aspiration in the treatment of high-load kidney stones and kidney stones combined with infection, provide a more scientific treatment strategy for clinical practice, and promote the application of negative pressure aspiration technology in the field of ureteral soft scope lithotripsy, providing new means and ideas for individualized treatment.


Eligibility criteria:
inclusion criteria: 150/5000 1. patients diagnosed with kidney stones with a diameter of 2-3cm by ct; 2. age \> 18 years old; 3. the anatomical structure of the kidney is normal, without deformity; 4. unilateral or bilateral kidney stones are not treated at the same time 5. no serious heart and lung disease (asa grade i-ii) 6. through preoperative communication, patients and their family members indicated that they were fully aware of the condition and the choice of treatment plan, and signed informed consent and informed choice notification; exclusion criteria: 1. simultaneous operation is required for ipsilateral ureteral calculi or contralateral upper or lower urinary calculi. 2. severe coagulation dysfunction; 3. previous history of ipsilateral upper urinary tract surgery; 4. presence of urinary anatomic abnormalities or congenital malformations; 5. patients who do not sign informed consent and cannot cooperate with the study;
the predictors of icu admission of opres

Conditions: Posterior Reversible Encephalopathy Syndrome; Intensive Care Units

Summary: the purpose of this study is to explore the predictors of icu admission of obstetric posterior reversible encephalopathy syndrome.

the investigators retrospectively collected data (general information, clinical data, biochemical indicators, imaging features, and pregnancy outcome) from pregnant woman diagnosed with pres to explore the predictors of icu admission during 2012 to 2021.then, the investigators grouped all the patients into icu group and non-icu group according to icu admission or not.

Eligibility criteria:
inclusion criteria: 1. pregnant women were diagnosed of pres. 2. all patients provided written informed consent exclusion criteria: 1. patients combined with other neurological disorders 2. patients combined with mental illness
a-klotho in relation to calcification in the coronary arteries and aortic valve in patients with chronic kidney disease

Conditions: Vascular Calcification; Chronic Kidney Diseases

Summary: to define the correlation of the levels of a-klotho with the severity of vascular calcification in the coronary arteries and aortic valve.

vascular calcification is a well-defined risk factor for cardiovascular disease and a-klotho has been suggested to be an implicating factor in the process of vascular calcification, particularly in patients with chronic kidney disease (ckd). with this study the investigators will examine the possible correlation of the levels of secreted a-klotho with the severity of vascular calcification in the coronary arteries and aortic valve in patients with ckd at different stages of ckd. more precisely, a-klotho was measured in 30 patients with end-stage renal disease under intermittent regular hemodialysis and 30 outpatients with stable ckd stage iii (estimated glomerular filtration rate between 30 and 59 ml/min/1.73\^2). participants in both groups were eligible only if stable for at least the last 3 months pre-enrollment. calcification will be calculated using the well-established agatston score after submitting all patients to multi-slice computed tomography. continuous variables will be described as median (25th-75th percentile) and categorical variables as n (%). variables will be compared between groups using the non-parametric mann-whitney u test for continuous and fisher's exact test for categorical variables. bivariate correlations of a-klotho levels with clinical variables and calcification scores using the spearman correlation coefficient will be examined. identification of a-klotho determinants, log-transformation of a-klotho levels was done because of log-normal distribution and stepwise linear regression was used, with probability to remove the variable\>0.1. identification of determinants of coronary and aortic calcification was done via log-transformation of the corresponding calcium scores, (a value of 0 was assumed; log-transformed-1 for absent calcium) and, stepwise linear regression was used as above. because of the small sample size, all regression estimates, and confidence intervals were calculated with re-sampling so that robust variable selection and stable estimates can be ensured.

Eligibility criteria:
inclusion criteria: * patients with stable chronic kidney disease stage v under intermittent hemodialysis and, patients with stable chronic kidney disease stage iii exclusion criteria: * active cancer * inflammatory or granulomatous disease * primary hyperparathyroidism * patients unable to provide informed consent
aerobic exercise on fitness score and blood glucose level in adolescents girls with diabetes mellitus

Conditions: Type 1 Diabetes Mellitus

Summary: in adolescent diabetic girls, a correct life style, including diet and physical activity, is part of a correct intervention protocol. thus, the aim of this study was to evaluate the effects of aerobic training intervention, based on heart rate at glycemic level , on clinical and physiological parameters in adolescent girls with type 1 diabetes forty type1 dm girls will randomly assigned to an intervention (study group ) or control group. the study group will perform a supervised aerobic exercise training based on heart rate whereas control group maintained their usual lifestyle. anthropometric fitness score measures, blood analysis will assess at baseline and after intervention.

fourty adolescents girls were diagnosed by physician as having type 1 diabetes mellitus and recruited from outpatient internal of el-hussien hospital in egypt . girls ages were between 13 and 18yr old; . the following inclusion criteria was applied to all participants in the study : all girls had type 1dm for more than 3 years, their dose of insulin intake over 0.4 u/kg/day, body mass index (bmi) between 25 and 30 kg/m2 . moderate-intensity aerobic exercise was defined according to the classification standard of the acsm, which refers to exercise where the hrr of subjects is 64-76%; the moderate-intensity target heart rate area was set in advance and controlled by heart rate monitor during the intervention, and the menarche was began from 3 to 5 years. the patients had no history of severe and frequent hypoglycemia in the last 6 months (\< 60 mg/dl, more than twice a week). all participants attended a clinic for clinical assessments before and after treatment plane. 1. body mass index (bmi) 2. fitness score 3. target heart rate 4. fasting blood samples, post prandial and hba1c: were taken for the following measurements: glucose. 5. estradiol blood test

Eligibility criteria:
inclusion criteria: * all girls had type 1dm for more than 3 years, * their didn't of insulin intake over 0.4 u/kg/day, body mass index (bmi) between 25 and 30 kg/m2 exclusion criteria: * diabetes as a secondary condition * any known cardiac defects and macrovascular or microvascular chronical complications. * insulin therapy and regulate dietary intake were followed through diabetes physician.
physical therapy versus internet-based exercise training for patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the purpose of this study is to examine the effectiveness of standard physical therapy and an internet-based exercise program for people with knee osteoarthritis (oa). both of these programs will be compared to a "waiting list" control group. the investigators hypothesize that both treatments will result in greater improvement than the control condition and that the treatments will be similarly effective. the investigators also expect that some patients may do better with one treatment type or another and will explore this.


Eligibility criteria:
inclusion criteria: * knee osteoarthritis exclusion criteria: * no internet access * rheumatoid arthritis, lupus, or any other rheumatic condition * severe fibromyalgia * gout in your knees * on a waiting list for joint replacement surgery, or are you planning to have joint replacement surgery during the next year * total knee replacement surgery, other knee surgery, a torn meniscus in your knee, or a torn acl in your knee during the past 6 months * hospitalized for a stroke, heart attack, heart failure, or had surgery for blocked arteries in the past 3 months * currently undergoing physical therapy for knee oa * meeting current recommendations for physical activity levels * participating in another interventional study related to knee osteoarthritis or a study that involves physical activity

Keywords: osteoarthritis knee osteoarthritis
efficacy of a 12-week regimen of telaprevir, pegylated interferon, and ribavirin in treatment-naive and prior relapser subjects with interleukin28b (il28b) cc genotype

Conditions: Hepatitis C, Chronic

Summary: the purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (peg-ifn-alfa-2a) and ribavirin (rbv) (t12/pr12) is safe and effective in subjects who have the interleukin-28b (il28b) cc genotype. the subjects enrolled in this study will have chronic hepatitis c virus (hcv) infection and will not have cirrhosis of the liver.


Eligibility criteria:
inclusion criteria: * male and female subjects, 18 to 70 years of age, inclusive * treatment-naive or subjects (prior relapsers) may be included who did not achieve sustained viral response 24 weeks after last planned dose of study drug (svr24) after at least 1 prior course of peg-ifn/rbv therapy of standard duration and had a documented undetectable hcv rna level at the planned end of treatment of at least 42-week duration * subjects have il28b cc genotype determined during screening * subjects have genotype 1 chronic hepatitis c and laboratory evidence of hcv infection for at least 6 months, defined by (1) documented hcv serology test at least 6 months before the first screening visit demonstrating the presence of anti-hcv antibody, or (2) documented presence of hcv rna by a sensitive and specific assay at least 6 months before the first screening visit, or (3) documented histologic evidence of chronic hepatitis c demonstrated by fibrosis on a standardized histologic grading system at least 6 months before the first screening visit. if only inflammation is present in the liver histologic report, then 6 months of laboratory evidence is required exclusion criteria: * subjects have received previous treatment with telaprevir or any other protease inhibitor(s) for chronic hepatitis c * subjects who did not achieve svr24 after at least 1 prior course of peg-ifn/rbv therapy of standard duration and never achieved undetectable hcv rna while on treatment * subjects have evidence of hepatic decompensation * subjects have evidence of cirrhosis * subjects have diagnosed or suspected hepatocellular carcinoma * subjects have any other cause of significant liver disease in addition to hepatitis c, which may include but is not limited to malignancy with hepatic involvement, hepatitis b, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, wilson's disease, nonalcoholic steatohepatitis, or primary biliary cirrhosis. steatosis is allowed if clinically asymptomatic

Keywords: vx-950 incivek incivo